From the remaining 30 candidate genes, the SLC44A2 gene was selected for validation due to its recent identification as a risk locus for both DVT and stroke (Germain et al., 2015; Hinds et al., 2016), both of which are pathologies associated with described contributions of platelet-leukocyte interactions. This evidence concerns the gene SLC44A2 and stroke disorder.